# Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

> **NCT07501650** · PHASE1 · RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 6 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Small Cell Carcinoma
- Metastatic Head and Neck Cancer
- Recurrent Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Definity
- **DEVICE:** Ultrasound-Induced Microbubble Cavitation

## Key facts

- **NCT ID:** NCT07501650
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2027-03
- **Final completion:** 2028-03
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07501650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07501650, "Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07501650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*